vialaudit
LIRAGLUTIDE·INDIANA·LAST CHECKED 1 NOV 2026

Is Liraglutide legal in Indiana?

CAVEATS APPLY

Since 1 Jul 2026 Indiana law (IC 16-42-22.5) bars compounding from research-grade or veterinary-grade bulk ingredients outside an IRB-approved study and requires an FDA-registered source with a certificate of analysis. From 1 Jan 2027 medical spas must register with the state medical board. Federally: Yes, as a prescription drug: FDA has approved it (Victoza, Saxenda, generics). A vial sold as a 'research peptide' is not the approved product, and selling it for human use breaks federal drug law. Pharmacies may compound it only when the product is not a copy of the approved drug.

CATEGORY · FDA APPROVED

Full status breakdown

FEDERAL · STATE · SPORT-BODY

Federal status

FDA approval
approved as drug · brand: Victoza, Saxenda · NDA 022341 (Victoza); NDA 206321 (Saxenda) · approved Jan 25, 2010
Indications: T2DM (Victoza); chronic weight management (Saxenda); CV risk reduction in T2D with CVD
DEA scheduling
not scheduled
503A compounding
FDA interim category: Component of an FDA-approved drug
503A Bulks List: not on list
Component of approved drugs (Victoza, Saxenda and generics), so 503A compounding is limited by the 'essentially a copy' rule. Included in FDA's 1 May 2026 proposal to exclude GLP-1s from the 503B clinical-need list; no final notice as of 12 Oct 2026.
FDA Warning Letters
none on record for this compound
Shortage status
not currently on shortage list
Historical shortage window: Jan 1, 2023 → Sep 30, 2024
Sale framing
Research-use-only posture: Liraglutide is FDA-approved; selling as 'research peptide' misrepresents an approved drug and exposes seller to FDCA §301 misbranding and DOJ unapproved-diversion enforcement.
Personal possession: Not federally criminalized (not a controlled substance). Possession of unapproved or counterfeit liraglutide is a regulatory rather than criminal matter at the federal level.

Indiana — state-specific

compounding restriction · Indiana

Since 1 Jul 2026 Indiana law (IC 16-42-22.5) bars compounding from research-grade or veterinary-grade bulk ingredients outside an IRB-approved study and requires an FDA-registered source with a certificate of analysis. From 1 Jan 2027 medical spas must register with the state medical board.

Sport-body status

WADA 2026
not prohibited
GLP-1 receptor agonists are not on the 2026 Prohibited List.
USADA
not banned
NCAA
unknown

What we couldn’t verify

Also known as

4 ALIASES

Liraglutide is also marketed or referenced under the following names (vendor pseudonyms, brand names, chemical identifiers):

  • Saxenda
  • Victoza
  • NN2211
  • Lira

Related

FOLLOW-ONS

Liraglutide: US status, sources and what changed

Other states with a rule that names Liraglutide: California. Everywhere else, federal law applies.

THE ROUNDUP · MONTHLY

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 SUBSCRIBERS·0 SPONSORED ITEMS·11 ISSUES SINCE LAUNCH